Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of
non-small cell lung cancer (NSCLC) have increased survival in metastatic EGFR-mutated NSCLC.
However resistance to therapy can develop.
NSCLC tumors with EGFR-activating mutations are exquisitely sensitive to EGFR tyrosine kinase
inhibitors with overall response rates approximating 80%. The third generation EGFR compound
osimertinib is a standard first line option. Resistance to the third generation EGFR-TKI
osimertinib can develop with a median PFS of 18.9 months. Current research examining acquired
resistance to EGFR-TKIs has focused on overcoming these main mechanisms of EGFR-TKI
resistance and understanding the impact of co-occurring alterations. Frequently altered
pathways concomitantly affected with EGFR in lung cancer are cell cycle genes. This study
will explore a strategy to inhibit EGFR and CDK4/6 in resistant EGFR mutated lung cancer
patients post progression on osimertinib.